JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
Protean Small Cap beat its benchmark in December. It returned 0.3%, while the index retracted by -0.1%. Click here to read ...
Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...
Structure Therapeutics is preparing to begin ... Furthermore, GPCR anticipates that upcoming results from their CagriSema trials over the next year could further validate the mechanism of action ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...
Cagrisema is only as good as Zepbound ... dual chamber pen manufacturing in order to introduce this structure to the market." "This disappointing result will increase investor concern on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback